Resin hemoperfusion in dogs intoxicated with ethchlorvynol (Placidyl®)  by Zmuda, Michael J.
Kidney International, Vol. 17 (1980), pp. 303 -311
Resin hemoperfusion in dogs intoxicated with ethch!orvynol
(Placidyl®)
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Resin hemoperfusion in dogs intoxicated with ethchlorvynol
(Placidyt). Kinetic parameters were studied to determine the
effectiveness of hemoperfusion in removing ethchlorvynol from
the plasma and red blood cells (RBC) of intoxicated dogs. Per-
fusion columns contained polystyrene/divinyl benzene resin
(XAD-4 Amberlite®). Column clearances of ethchlorvynol aver-
aged 96.5 0.4% of the plasma flow rate (mean SEM, 9 dogs).
Plasma ethchlorvynol t1/2's during preperfusion periods averaged
94.1 hr. During hemoperfusion, t'/2'S averaged 3.8 hr. or 90.3 hr
shorter than at the endogenous rate of detoxication. There was
no significant difference between preperfusion and postperfusion
half lives. An estimate based on plasma column clearance sug-
gests that 1.5 0.1 g ethchlorvynol, or 19.0 2.8% of the dose,
was removed by hemoperfusion, The amount eluted from the
resin was 2.9 0.3 g (37.2 5.8% of the dose), or about twice
the amount apparent from plasma clearance alone. Further, the
volume of distribution of ethchlorvynol was 2.3 0.2 liters/kg,
suggesting significant distribution to intracellular and extravas-
cular compartments. The results show that resin hemoperfusion
removes a large fraction of ethchlorvynol from intoxicated dogs,
and greatly adds to endogenous mechanisms for elimination.
Ethchlorvynol was removed from RBC directly, and ultimately
from extravascular sites as well.
Hémoperfusion sur résine chez des chiens intoxiqués par
l'éthchlorvynol (Placidyl®). Afin de determiner l'efficacité de
l'hémoperfusion dans Ia soustraction d'éthchlorvynol du plasma
et des hématies de chiens intoxiqués, les paramètres cinétiques
ont été mesurés. Les colonnes de perfusion contenaient une ré-
sine polystyrCne/divinyl benzène (XAD-4 Amberlite®). La clear-
ance de l'éthchlorvynol par les colonnes était en moyenne de
96,5 0,4% du debit plasmatique (moyenne SEM, 9 chiens). La
plasmatique de l'ethchlorvynol tV2's pendant Ia période prëalable
ala perfusion Ctait de 94, 1 heures. Pendant l'hémoperfusion, tV2's
était en moyenne de 3,8 heures, soit 90,3 heures de moms qu'au
cours de Ia détoxication spontanée. II n'a pas Cté observe de
difference entre les demi vies avant et après perfusion. Une esti-
mation fondée sur Ia clearance des colonnes suggére que 1,5
0,1 g d'éthchlorvynol, soit 19,0 2,8% de Ia dose a été soustrait
par l'hémoperfusion. La quantité éluée de Ia résine a été de 2,9
0,3 g (37,2 5,8% de Ia dose), soit le double de Ia quantité
évaluée a partir de Ia clearance du plasma. De plus, le volume de
distribution de l'éthchlorvynol était de 2,3 0,2 litres/kg, ce qui
suggère une distribution importante dans les compartiments in-
tracellulaire et extravasculaire. Les résultats montrent que
l'hémoperfusion sur résine soustrait une fraction importante de
l'éthchlorvynol chez des chiens intoxiqués et ajoute une élimina-
tion importante aux mécanismes endogènes. L'éthchlorvynol a
été soustrait des hématies directement et finalement des sites
extravasculaires aussi.
303
It is known that risks of morbidity and mortality
from poisoning increase with the length of recov-
ery, particularly when stage-TV coma is involved
[1—3]. Some central-nervous-system depressants,
including ethchlorvynol, have elimination half-lives
(tV2) that exceed 100 hr [4]. Recovery from stage-TV
coma could take many days because 3.3 half-lives
are needed to remove 90% of the drug, assuming a
constant rate of elimination. The use of hemoper-
fusion is justified if it can significantly add to en-
dogenous elimination [1, 5, 6] and thereby shorten
the recovery time.
Three types of adsorbents have been used in per-
fusion devices for drug removal: activated charcoal,
ion-exchange resins, and aromatic resins [7]. The
aromatic resins, XAD-2 Amberlite® and XAD-4 Am-
berlite® (Rohm and Haas Co., Philadelphia), have a
special affinity for lipophilic drugs [8]. The XAD-4
resin is commercially available and has more than
twice the surface area, greater porosity, but a small-
er average pore size than the earlier version.
Aromatic resins have been studied in vivo in dogs
and humans intoxicated with barbiturates [8-13],
cephalothin and clindamycin [14], digoxin [15-17],
ethchlorvynol [10], glutethimide [8—10, 13], meth-
aqualone [11], methotrexate [18], theophylline [19],
and tricyclic antidepressants [13]. In vitro perfusion
with the XAD-4 resin has been tested for adsorption
of procainamide, N-acetylprocainamide, and quini-
dine [20].
Aromatic resin hemoperfusion in ethchlorvynol
intoxication has been reported only in a single hu-
man patient [10] and involved the earlier XAD-2
Received for publication April 3, 1979
and in revised form August 9, 1979
0085-2538/80/0017-0303 $01.80
© by the International Society of Nephrology
304 Zmuda
resin. As many as nine human patients [21, 22] and
one dog [23] intoxicated with ethchlorvynol have
been perfused with activated charcoal, but reports
of XAD-4 perfusion in ethchlorvynol intoxication
could not be found in the literature. Therefore, its
ability to add to the endogenous elimination of this
drug has not been established.
Hemoperfusion often has involved more than one
removable drug, and its usefulness in single drug
poisoning seems obscure. Effectiveness in multiple
drug poisoning may be difficult to define without
first characterizing its single drug capability. The
present study tested XAD-4 perfusion in single drug
intoxications, and effectiveness was assessed by
comparing its drug removal rate to the rate of en-
dogenous elimination.
Methods
Mongrel male or female dogs (mean weight, 22.1
kg) were given 350 or 400 mg/kg liquid ethchlorvy-
nol peroral. The animals were fasted for 48 hr and
deprived of water for 24 hr to maximize drug ab-
sorption and minimize pulmonary complications.
The viscous drug was administered through a poly-
ethylene (PE-240) stomach tube which was then
flushed with saline to assure quantitative delivery.
The dogs became comatose, and surgery could be
performed without supplemental anesthesia within
5 hr of dosing. Assessment of stage-IV coma was
based primarily on the need for respiratory assist-
ance [3]. The animals were intubated with a cuffed
endotracheal tube, and vital signs were monitored
periodically. During perfusion, animals that exhib-
ited the righting reflex were supported upright in a
sling and frame (Alice King Chatham Medical Arts,
Los Angeles, California), thus preventing the
need for supplemental anesthesia.
Blood sa,npiing. Plasma ethchlorvynol concen-
tration was followed before, during, and after he-
moperfusion to compare elimination half-lives be-
tween these periods. This provided a rigorous as-
sessment of effectiveness, with each animal as its
own control. Blood was drawn initially from a bra-
chial vein by percutaneous puncture until the ani-
mals could tolerate surgery and then from a cathe-
terized jugular vein for all other preperfusion and
postperfusion samples. A dextrose-in-saline solu-
tion was administered through an i.v. apparatus set
to maintain patency and provide fluid replace-
ment. The samples were drawn after temporarily re-
moving slightly more than the tubing deadspace vol-
ume into another syringe while the i.v. drip was
blocked. Syringes for preperfusion and post-
perfusion samples were heparinized with very small
volumes of concentrated heparin (10,000 U/ml) to
avoid diluting the drug. A femoral artery and vein
were catheterized for perfusion, and samples were
drawn from each of the inflow and outflow lines of a
pediatric arteriovenous blood-tubing set. Systemic
heparinization (325 to 425 U/kg) during perfusion
enabled the use of nonheparinized syringes. Dupli-
cate hematocrits (Hct) were measured periodically
from preperfusion and postperfusion samples and
from all hemoperfusion samples.
Hemoperfusion. Custom-made columns (Extra-
corporeal Medical Specialties Inc., King of Prussia,
Pennsylvania) contained about 430 g (wet weight) of
copolymeric polystyrene and divinyl benzene resin
(XAD-4 Amberlite®). The resin was primed by per-
fusing 4 to 5 liters of heparinized saline (10,000 U/
liter) through the column, and was degassed by
hammering the cylinder wall with a soft-headed
mallet. Degassing and priming were considered sat-
isfactory when bubbles no longer issued into the
outflow line and the collected saline was clear and
free of particulate. A dialysis roller pump was cali-
brated during priming by measuring 1-mm samples
at varied pump settings. Anaeroid manometers and
fluid barriers (Extracorporeal) were attached to the
inflow and outflow pressure monitor lines of the
blood-tubing set to measure the pressure gradient
across the column. The hemoperfusion circuit was
tested for leaks by clamping the outflow line while
saline was being perfused at about 200 mI/mm
through the system. Pressure in both lines was al-
lowed to rise to 500 mm Hg before pump speed was
reduced to zero. Rarely a column had to be re-
placed, and subtler leaks that caused a persistent
loss of pressure were minimized by resecuring con-
nections.
About half the volume of the priming solution
(130 to 135 ml) was infused into the femoral vein at
the start of perfusion to minimize the risk of shock.
Blood flow rate was increased to 150 mllmin usually
within 2 mm and was maintained. Pressure about
the column became stabilized within 5 mm at 130 to
160 mm Hg in the inflow line and 70 to 90 mm Hg in
the outflow line. An increase of 20 mm Hg or more
in the inflow line only suggested coagulation in the
column and was treated by injecting 1000 or 2000 U
of heparin into the inflow line. Coagulation was
avoided to assure continued blood flow over the
maximum surface of resin and to simplify quan-
titative recovery of drug during elution.
Resin elution. At the end of perfusion, blood was
returned to the animal by gravity feed. One of the
ends of the cartridge was forcibly removed, and the
resin was transferred to an empty oversized car-
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tridge (Extracorporeal) because the resin expanded
on addition of methanol. Cold saline (800 to 1000
ml) was poured onto the resin and collected as frac-
tion I until the blood had come off and the original
color of the resin was apparent. Then, several 300
to 500 ml fractions of methanol were added and col-
lected at 4 to 5 mllmin. Because the resin absorbed
methanol, the volume of each collected fraction was
measured before being analyzed. Collection of frac-
tions was continued until ethchlorvynol was essen-
tially undetectable.
Ethchlorvynol analysis. Concentrations in
plasma, RBC, urine, and methanol elution samples
were determined routinely by the spectrophoto-
metric method of Haux [24] with the following
minor changes. Plasma was used for the blank in
lieu of water, and 6 ml chloroform rather than 3 ml
was used for the extraction to provide the minimum
readable volume in a standard cuvette of a spectro-
photometer (Spectronic-20). Four working standards
containing 5, 10, 20, and 30 pg!ml in ethanol
were determined with each analysis and comprised
the linear range of the spectrophotometer. Un-
known samples having concentrations in excess
of 30 jiglml were carefully diluted to within the
linear range.
Calculations. Plasma column clearance of eth-
chiorvynol as a percent of plasma flow rate (F0) was
calculated by the equation [(I—O)/I]100, where I
and 0 were plasma drug concentrations in the in-
flow and outflow lines, respectively. This ex-
pression can be interpreted without knowing whole
blood flow rate (Fb), hematocrit, or F0, and is simi-
lar to the extraction ratio used by others [7, 22].
The amount of drug removed from plasma based
on column clearance (A0) was calculated by an ad-
aptation of the trapezoidal rule [25]:
A0 = T/2([(I — O)F0]0 + 2[(I — O)F0]1
+ 2[(I — O)F0]2 +
2[(I — O)F0]0_1 + [(I — O)F0]0)
T was the time between samples, and F0 was esti-
mated from Fb(l — Hct) for each collection period.
The subscripted numbers identify consecutive
sample pairs having equal time intervals. The I — 0
difference and F0 were assumed to be constant be-
tween collections. This potential error was mini-
mized by frequent sampling at short intervals. The
total amount removed based directly on elution of
the resin (Ar) was obtained by summing the prod-
ucts of concentration times volume from the col-
lected fractions.
The drug elimination half-life (t1/2), peak plasma
drug concentration (C0), and rate constant of elimi-
nation (Ke) were determined objectively for each
of the preperfusion, hemoperfusion, and postper-
fusion periods by applying the least-squares sta-
tistical method to plasma drug concentrations and
time (t), in hours, after dosing. A least-squares com-
puter program converted drug concentration to the
natural logarithm, base e (ln). Therefore, when drug
concentration versus time was plotted on semi-
logarithmic coordinates, Ke was directly equivalent
to the slope of a best-fit line that described the
rate of elimination. Ke was calculated by the equa-
tion ln(Cb!Ca)/T, where Ca and Cb were plasma drug
concentrations at any two points a,b on the line,
and T was the time tb — ta between these points.
The half-life is determined by Ke and was given by
the standard equation 0.693/Ke, where — 0.693 is
In('/2). Mean half-lives were determined by first
taking the mean of the Ke'S from each period and
then solving the equation.
The best-fit line was given by the equation [1n(C)
= ln(C0) + Ket] where C is a statistical drug con-
centration corresponding to any chosen t based on
the least-squares averaging of observed concentra-
tions. When t = 0, the peak plasma concentration
(C0) is obtained and is the zero time intercept of the
preperfusion line. C(, was used to estimate volume
of distribution (Yd) by the equation XO/CO, where X0
was the dosage in milligrams per kilogram of body
weight and C0 was expressed in milligrams per liter.
To be valid, all of the drug must be absorbed or
Vd would tend to be overestimated. Thus, an alter-
native approach was used that is relatively inde-
pendent of drug absorption and makes use of a
theoretically similar relationship between the net
decrease in concentration due to hemoperfusion
(LCh) and the amount of drug eluted from the resin
(Ar). This Vd was given by the equation Ar/Cn,
where Ar was expressed in milligrams per kilogram
of body weight and zCh in milligrams per liter. zCh
was estimated by taking the difference [B — A], where
B and A were the Ce's obtained when the equations
of the preperfusion and postperfusion lines, re-
spectively, were solved for the moment hemoper-
fusion ended (usually C34). Endogenous elimination
during perfusion was excluded, and a postperfu-
sion rebound in concentration was included in in-
terpolating B and A.
Observed plasma drug concentrations that were
significantly changing due to drug absorption or to
distribution and redistribution phenomena were ex-
cluded from the derived pharmacokinetic parame-
ters by evaluating the error of prediction in the least-
squares program. This was to assure that the data
Net change
Preperfusion in plasma
= 412.1 tart concentration
o0pertusion!
End Postperfusion
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represent the constant elimination phase of each
of the preperfusion, hemoperfusion, and postper-
fusion periods. In a few cases, statistically ex-
cluded concentrations were included if they caused
no significant change in Co, Ke, or half-life, and con-
centrations in all samples taken from the inflow line
during perfusion were always included.
The elimination of ethchlorvynol seemed to obey
apparent first-order kinetics because the milligram
quantity eliminated with time decayed with the
plasma concentration but in a proportionally con-
stant manner. Even though dosage, the length of the
preperfusion and hemoperfusion periods, the size
of the columns, and the Fb were not varied, the
drug concentrations at the start of perfusion and
zCh ranged widely and seemed to have a poor
relationship to the effect produced in terms of the
hemoperfusion Ke. This led to the derivation of
a parameter that expresses the net change in drug
concentration as a proportion of the beginning con-
centration. This parameter is given by the equation
[P1!2 = ln(A/B)! — 0.693], where PV2 is the number
of times the plasma concentration decreased by one
half. Though arithmetically unitless, P!2 was as-
signed units of half-lives. P1/2 is expected to increase
with the length of perfusion if Fb and the relative
drug binding capacity or quantity of resin in the col-
umn do not change. However, P'!2 should be con-
stant for a given time period and independent of
the beginning plasma concentration if the rate of
elimination is proportionally constant.
The statistical significance of difference in param-
eters between periods was determined by the depen-
dent groups f-test. In the case of half-life, this test
was applied to the Ke differences between periods.
Results
The observed plasma ethchlorvynol concentra-
tions from a typical experiment are shown in Fig. 1
with the best-fit lines and related data. By com-
parison, the therapeutic range in the adult human
has been reported to be 1 to 8 tgJml [24]. This ani-
mal became comatose within 1.6 hr of dosing and
required respiratory assistance by 4.0 hr (stage-IV
coma). All perfused animals were in stage-tV coma at
the beginning, awoke sometime during, and slept
but would arouse when handled following the he-
moperfusion period. One nonperfused dog remained
comatose during a 5-day observation period.
The shallow slope of the preperfusion line yielded
a biologic V/2 of 412.1 hr (17.2 days). A half-life of
such considerable length reflects that plasma con-
centration was changing very slowly and endoge-
nous elimination was essentially negligible. The
concentrations between 10 and 30 hr decreased by
only 3.1 jxg/ml and support this point. Half-lives dur-
ing preperfusion and postperfusion periods of other
experiments (Table 1) ranged widely, and a few
were negative because the best-fit lines had slightly
increasing slopes. In contrast, half-lives during per-
fusion were considerably shorter and made up a
much narrower range. The mean difference be-
tween preperfusion and hemoperfusion t72's was
90.3 hr (3.8 days) and is the additional time endoge-
nous mechanisms would have taken to eliminate the
amount of drug removed by 4 hr of perfusion. There
was no significant difference between preperfusion
and postperfusion half-lives.
The substantial decrease in concentration in the
first 12 mm of perfusion (Fig. 1) was observed in all
other experiments and was excluded from deriva-
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Fig. 1. Concentration-time course of a typical hemoperfusion experiment. Circles denote the observed plasma ethchlorvynol concentra-
tions;filled triangles, the statistical concentrations from a least-squares analysis; (B) and (A). the statistical concentrations at the instant
hemoperfusion ended based on the preperfusion and postperfusion lines, respectively. The best-fit lines were drawn between the pairs of
filled triangles at times 0 and 30 hr (preperfusion), 30.2 and 34 hr (hemoperfusion), and 34 and 42 hr (postperfusion).
Resin hemoperfusion in ethchlorvynol intoxication .307
tion of the best-fit lines and half-lives because it did
not seem representative of the constant and slower
rate of elimination that followed. In one experi-
ment, four samples were drawn from the inflow line
at 3-mm intervals initially, and it was found that the
concentration decreased by 54.3 pg/ml (26.2%)
within the first 3 mm of perfusion. This decrease
represented 42% of the net change in concentration
produced by the total 4-hr perfusion period in this
experiment. None of the priming solution was given
Table 1. Half-lives (tV2) of ethchlorvynol in intoxicated dogs
treated with 4 hr of aromatic resin hemoperfusiona
Exp. No.
tV2, hr
Preperfusion Hemoperfusion Postperfusion
1 57.0(22) 4.2 97.1 (8)
2 59.6 (22) 5.5 40.6 (10)
3
—882.4 (19) 3.4 91.1 (6)
4 79.9 (24) 6.0 —193.7 (9)
5 29,9 (24) 2.4 120.2 (9)
6 445.7 (18) 4.1 57.8 (10)
7 412.1 (18) 3.7 70.5 (11)
8 114.6 (23) 6.9 1281.9 (11)
9 323.9 (13) 2.5 372.9 (13)
Mean" 94.1 3.8 107.1
Number in parentheses equals number of plasma ethchlorvy-
nol determinations contributing to the preperfusion and post-
perfusion half-lives. Each perfusion half-life was based on 13 in-
flow plasma ethchlorvynol determinations taken at 12- and 24-
mm intervals.
b This was obtained from the mean slope of each period. Mean
difference between preperfusion and hemoperfusion half-lives is
statistically significantly (P < 0.0005).
Table 2. Summary of ethchlorvynol column clearance and the
amount of drug removed during hemoperfusion of several dogs
intoxicated with ethchlorvynol
Ethchlorvynol
column clearancea
Ethchlorvynol removed"
A Ar A9 Ar
Exp. no %F9 mg %of dose
1 95.5 2.7 961.7 1701.5 11.8 20.8
2 96.5 2.1 901.0 1844.3 10.4 21.6
3 97.5 2.3 1474.8 3139.1 15.2 32.2
4 97.6 2.2 1223.6 2349.1 10.6 20.4
5 96.8 3.5 1421.3 2753.9 26.2 50.8
6 97.0 2.6 1815.8 4121.0 29.3 66.5
7 94.9 3.3 1938.3 3728.3 25.8 49.6
8 98.1 1.7 1517.1 2865.4 12.0 22.7
9 95.0 4.4 1930.6 3238.4 29.8 50.0
Mean 96.5 1464.9 2860.1 19.0 37.2
SEM 0.4 129.0 269.0 2.8 5.8
a Clearance is expressed as a percent of plasma flow rate (F,,).
Mean SD of each individual experiment was based on 13 pairs
of inflow and outflow samples taken during perfusion.
A,, is the amount of drug removed from plasma alone; Ar, the
amount of drug eluted from the resin. Mean difference between
A,, and Ar of 18.2% is statistically significant (P < 0.0005)
to this animal, suggesting that the decrease was not
a dilutional effect from administered fluid.
The statistical concentrations are also shown in
Fig. 1. The difference between C30 and C34(B) shows
that a very small decrease in concentration resulted
from endogenous elimination during perfusion. The
difference between C34 based on the hemoperfusion
line and C34(A) indicates that a large cumulative
postperfusion rebound occurred. Nevertheless,
with both factors considered in the calculation, the
net change in concentration (ACh or [B — A]) dem-
onstrates that a substantial effect resulted relative
to that expected by endogenous elimination alone.
Table 2 lists data from several experiments sum-
marizing the extraction of drug by hemoperfusion.
Column clearances were extremely uniform. The
total amount eluted from the resin (Ar) was about 2
times the amount removed from plasma (A0) and
implies that much more drug was extracted than can
be accounted for in plasma alone. The size of Ar
indicates that a substantial percentage of the body
drug burden was removed.
Extraction of drug from RBC's was tested direct-
ly in one experiment, and the data is plotted in Fig.
2 as a concentration-time curve of the ethchlorvy-
nol differences between inflow and outflow samples
of RBC's (solid line) and plasma (dashed line). The
amount removed from RBC's was slightly but con-
sistently greater than that from plasma. A RBC/
plasma concentration ratio was found to be 1.12
0.05 (mean SD, 13 inflow samples) and indicates
that there was 12% more drug available in RBC's
than in plasma. The RBC/plasma concentration ra-
tio from 13 outflow samples was 2.73 1.49, in-
dicating that relatively more drug was left in RBC's
than in plasma. This experiment corroborates the
data in Table 2 and shows that a substantial amount
of drug being extracted came from RBC's.
Apparent volumes of distribution (Vd) of eth-
chlorvynol using two methods of calculation are
compared in Table 3, and the small difference in
means reflects good agreement between these
distinct approaches. Vd approximates a hypotheti-
cal volume needed to accommodate both the drug
amount (X0 and Ar) and plasma concentration (C0
and ACh) that are used in its calculation. Because
whole blood volume in the dog has been estimated
to be 0.08 liters/kg [26], Vd of the sizable magnitude
shown indicates major accumulation in one or more
extravascular compartments. Because the product
of blood volume times ACh is only 3.5% of Ar and
therefore cannot account for the sizable amount re-
moved, a Vd based on these values implies that
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Fig. 2. Comparison ofthe amount ofdrug removedfrom RBC's (R) and plasma (P) based on differences between drug concentrations in
samples taken from the inflow (I) and outflow (0) lines during a single hemoperfusion experiment,
most of the ethchlorvynol removed originated from
the extravascular compartments.
Figure 3 graphically shows the data from a con-
trol experiment in which hemoperfusion was omit-
ted and the animal allowed to detoxify itself through
the first biologic half-life. The observed peak con-
centration at 11 hr was 150 .tgJml, and the first t'/2
concentration of 75 pg/ml was reached at 83 hr (3.5
days). This is an observed 0/2 of about 72 hr and
lends credence to the statistically determined value
shown above the best-fit line.
The effect of perfusion in terms of a proportional
change in plasma concentration (P'/2) is shown in
Table 4. Based on the mean preperfusion half-life
(Table 1), 3.9 days would have been needed to de-
Table 3. Summary of volumes of distribution in ethchlorvynol-
intoxicated dogsa
Wt
Volume of distribution
Xo/Co Ar/LC5
Exp. no. kg liters/kg
1 25.5 2.51 2.11
2 24.8 2.56 2.21
3 24.3 2.84 2.01
4 28.8 3.21 3.33
5 13.8 1.31 2.47
6 15.5 2.24 2.78
7 18.8 1.79 1.63
8 31.5 2.97 2.48
9 16.2 1.80 1.56
Mean 22.1 2.36 2.29
SEM 1.9 0.21 0.19
Two approaches to estimating Vd are compared. X, is the
dosage; C0, the statistical peak plasma concentration; A,, the
amount eluted from the resin; Ch, the net change in plasma con-
centration during perfusion. The mean difference between Vd's
of0.07 liters/kg (3.1%) is not statistically significant (P = 0.4).
crease plasma concentration by one half-life if per-
fusion had not been performed. In contrast, the
mean PV2 shows that the plasma concentration was
decreased through an average of nearly one half-
life by 4 hr of perfusion.
Discussion
The data demonstrate that hemoperfusion with
XAD-4 Amberlite resin removed a significant
amount of ethchtorvynol from intoxicated dogs
even though the net change in plasma concentration
was not striking. It also was shown that drug
was removed from RBC's as well as plasma, but
that the bulk of removed drug originated from
extravascular compartments. Gibson et a! [15]
demonstrated that digoxin was removed by resin
perfusion also from the RBC's of dogs, but that
clearance rates between central and peripheral
compartments differed with the largest depot equili-
brating slowly. In the present study, relatively more
drug was left in RBC's than in plasma of outflow
samples, supporting the theory of differences in in-
tercompartmental clearance rates. Past perfusion
studies often were assessed with an assumption of
single compartment behavior and therefore may
have overestimated the effect produced.
Column clearances and halflives during perfusion
demonstrated that ethchlorvynol was removed at a
highly efficient and stable rate through the 4-hr peri-
od. The low variability seen particularly in clearance
values was striking (Table 2). Koffler et al
[22] treated eight ethchlorvynol-intoxicated hu-
man patients with fixed-bed charcoal perfusion and
observed plasma extraction ratios between 51% and
71% of the plasma flow rate. Five of the eight pa-
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Fig. 3. Observedpias,na ethchlorvynol concentrations and best-fit line of a single control experiment in which the animal was allowed to
detoxify itself through the first biologic half-life. The best-fit line was fitted to the observed concentrations from 5 to 100 hr.
tients were intoxicated with ethchlorvynol alone.
At least two factors could account for the apparent
discrepancy between charcoal and resin perfusion:
(1) the amount of adsorbent available; and (2) the
adsorption of heparin. The patients of Koffler et al
had less than half the amount of adsorbent available
to them and probably two or more times the body
weight of the dogs. Significant heparin adsorption
on charcoal was recently demonstrated [27], but
similar studies with resins apparently have not been
reported. The use of anticoagulant is unavoidable,
and its adsorption would decrease available sites.
Competitive differences may exist, however, be-
tween the adsorption of heparin, other anti-
coagulants, and various depressant drugs, and these
may differ from one adsorbent to another.
Teehan et al [28] found a mean biologic t'/2 of 72
hr (range, 21 to 105 hr) in four ethchlorvynol-in-
toxicated patients. They also observed a mean t'/2
Table 4. Expression of the net decrease in plasma concentration
duringperfusion as a proportion of the beginning concentrationa
Plasma ethchlorvynol
concentrations
PV2C34(B) C34(A)
Exp. no. pg/mi tV2
1 85.4 53.8 0.668
2 93.8 60.2 0.641
3 144.2 80.1 0.849
4 92.2 67.7 0.445
5 133.0 52.1 1.352
6 169.5 73.9 1.197
7 211.6 89.6 1.240
8 109.8 73.1 0.587
9 206.4 78.3 1.398
Mean 138.4 69.9 0.931
SEM 16.1 4.2 0.122
Statistical plasma concentrations at the instant hemo-
perfusion ended (C34) are based on the preperfusion (B) and post-
perfusion (A) lines. PI2 is the number of times the plasma con-
centration decreased by one half as a result solely of hemo-
perfusion.
of 21.8 hr (range, 6.3 to 44 hr) during dialysis. In
another study involving ethchlorvynol [29], deter-
mination of the amount of drug recovered in the
dialysis bath and the amount ingested showed that
22.3% was removed from one patient dialyzed for a
total of 14 hr, and 32.0% removed from another af-
ter 18 hr of dialysis. In comparison, the data in Ta-
bles 1 and 2 suggest that resin perfusion removes
the drug at a much faster rate than does dialysis and
would seem to be more time- and cost-effective.
Rosenbaum et a! [10] perfused a patient in-
toxicated with ethchlorvynol plus glutethimide, bu-
talbital, salicylate, phenacetin, and caffeine for 3 hr.
Ethchlorvynol clearances ranged widely from 287
mI/mm (95.7% of the whole blood flow rate) to 155
ml/min (5 1.7%). The XAD-2 resin that was used
has a lower capacity than the XAD-4 has [30], and
because glutethimide and butalbital also were re-
moved, it is likely that the resin became saturated.
It was estimated that 1506 mg of ethchlorvynol was
removed even though plasma concentration de-
creased by only 10 tg/ml. Using the beginning and
ending concentrations shown in Table 1 of their re-
port, we calculated a perfusion tV2 and found it to be
8.27 hr, just slightly longer than those of the present
study despite the capacity difference between res-
ins. A P'/2 also was calculated to be 0.363 t'/2'S
through the 3-hr perfusion, or 0.483 tV2'S when
adjusted to compare with the 4-hr values in Table 4.
It was not indicated whether plasma concentration
rebounded after perfusion, thus the P'/2 may be
overestimated. Nevertheless, a greater effect of
perfusion may have been realized than the change
in plasma concentration alone seems to suggest.
First-order elimination kinetics implies that a de-
crease in plasma concentration from 300 to 150 g/
ml is quantitatively the same as from 100 to 50 tg/
ml because proportionally they are equal. If the
time involved in each is the same, the rate of elimi-
nation is also proportionally constant, and even
200
100
70
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though the net decrease of one is three times the
other, the time required to achieve each would be
the same. Expression of the effect of perfusion as
P1!2 (Table 4) describes the decrease in concentra-
tion as a proportion in units of a one-half concentra-
tion. It characterizes how much of an effect was
produced by perfusion when the laws of first-order
kinetics are obeyed. In contrast, the half-life in-
dicates the rate of effect. Unlike estimates of the
amount removed based on clearance, p1/2 should
not vary with the beginning or changing concentra-
tions but only with the ongoing rate of elimination
which has more bearing on the detoxication being
achieved. It therefore can be used to identify dy-
namic and kinetic factors that alter perfusion ef-
fectiveness. It can be applied when preperfu-
sion and postperfusion data are lacking by tak-
ing B and A as the concentrations before and after
perfusion, respectively. This, however, would in-
clude endogenous elimination during perfusion and
may exaggerate the effect more if a postperfusion
rebound is ignored.
Because endogenous elimination and the post-
perfusion rebound were taken into account, the de-
crease described by P'/2 (Table 4) is that which is
due solely to hemoperfusion. The sizable rebound
illustrated in Fig. I indicates that the effect of per-
fusion would have been significantly exaggerated if
the rebound had been ignored and thus was a
greater source of potential error. The phenomenon
of plasma rebound has been observed by others fol-
lowing both dialysis [28] and perfusion [15, 31].
These sources of error may have exaggerated the
half-lives, which were determined by established
methods. During the constant elimination phase of
perfusion, the half-life represented a composite of
several rate-discrete processes including metabolism
and excretion (which added to the apparent rate of
elimination and decreased the half-life), and redistri-
bution from fat and brain tissues (which decreased
apparent elimination and increased halilife). If,
however, only the rates of redistribution from ex-
travascular compartments are considered, a slower
rate would have the misleading effect of decreasing
the apparent haiflife, assuming a constant rate of re-
moval by perfusion. Both the large initial decrease
in concentration at the start of perfusion and the
postperfusion rebound may have resulted from a
much slower rate of redistribution relative to re-
moval by perfusion. The fact that PV2's varied
widely suggests that redistribution rates may be dif-
ferent for a single drug depending on the pre-
dominant body compartment from which it is mobi-
lized, and may be expected to differ between drugs
depending on the tightness of binding at sites of ac-
tion and storage. In the case of fat-soluble drugs,
molecules may simply dissolve in lipid tissues and
would run out at a rate dependent on blood flow and
concentration gradient. Many drugs are subject to
both specific and nonspecific binding, however, and
in this case the rate of removal may depend at least
in part on a competitive relationship between tissue
and adsorbent binding characteristics. Thus, the
broad usefulness of perfusion in the future may be
contingent on a consideration of the chemistry of
binding moieties for the purpose of developing ad-
sorbents to be specific and selective for not only
drugs but endogenous poisons as well.
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